Glenmark Pharmaceuticals Q3 Results 2025:Glenmark Pharmaceuticals declared their Q3 results on 14 Feb, 2025, revealing a ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin ...

Inc., USA has launched the Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a product that is bioequivalent and ...

India's Glenmark Pharmaceuticals reported third-quarter profit below estimates on Friday due to bleak U.S. demand for its long-term illness drugs.

The company reported a loss of Rs 351 crore in the comparable quarter last year, hurt by sluggish sales in India and charges ...

Glenmark Pharmaceuticals reported a significant profit of Rs 348 crore for Q3 2024, rebounding from a Rs 351 crore loss in ...

Glenmark Pharmaceuticals reports strong revenue growth and expansion plans for dermatology and respiratory portfolios in ...

Glenmark Pharmaceuticals reported a consolidated profit after tax of Rs 348 crore in Q3 FY25, driven by strong regional ...

EBITDA zoomed to ₹600.3 crore in the third quarter over a loss of ₹208.7 crore in the year-ago quarter.  Shares of Glenmark ...

Glenmark Pharmaceuticals on Friday said its consolidated profit after tax stood at Rs 348 crore for the third quarter ended ...

Results: Glenmark Pharmaceuticals posted a net profit of ₹348 crore in Q3 FY25, reversing a ₹351 crore loss YoY. Revenue ...

Inc., USA, has announced the launch of Clindamycin Phosphate Foam, 1%, a product that is bioequivalent and therapeutically ...